Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma

Eslam, 2020, A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement, J Hepatol, 73, 202, 10.1016/j.jhep.2020.03.039 Younossi, 2021, From NAFLD to MAFLD: implications of a premature change in terminology, Hepatology, 73, 1194, 10.1002/hep.31420 Kang, 2021, From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: big wave or ripple?, Clin Mol Hepatol, 27, 257, 10.3350/cmh.2021.0067 Ng, 2022, Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: prevalence, outcomes and implications of a change in name, Clin Mol Hepatol, 28, 790, 10.3350/cmh.2022.0070 Kawaguchi, 2022, MAFLD enhances clinical practice for liver disease in the Asia-Pacific region, Clin Mol Hepatol, 28, 150, 10.3350/cmh.2021.0310 Cotter, 2020, Nonalcoholic fatty liver disease 2020: the state of the disease, Gastroenterology, 158, 1851, 10.1053/j.gastro.2020.01.052 Kang, 2021, KASL clinical practice guidelines: management of nonalcoholic fatty liver disease, Clin Mol Hepatol, 27, 363, 10.3350/cmh.2021.0178 Younossi, 2019, Non-alcoholic fatty liver disease – a global public health perspective, J Hepatol, 70, 531, 10.1016/j.jhep.2018.10.033 Kim, 2018, Association between non-alcoholic fatty liver disease and cancer incidence rate, J Hepatol, 68, 140, 10.1016/j.jhep.2017.09.012 Kanwal, 2018, Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease, Gastroenterology, 155, 1828, 10.1053/j.gastro.2018.08.024 Powell, 2021, Non-alcoholic fatty liver disease, Lancet, 397, 2212, 10.1016/S0140-6736(20)32511-3 Estes, 2018, Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030, J Hepatol, 69, 896, 10.1016/j.jhep.2018.05.036 Alexander, 2019, Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts, BMC Med, 17, 95, 10.1186/s12916-019-1321-x Yang, 2020, Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease, Hepatology, 71, 907, 10.1002/hep.30858 Bhaskaran, 2014, Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults, Lancet, 384, 755, 10.1016/S0140-6736(14)60892-8 Calle, 2003, Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults, N Engl J Med, 348, 1625, 10.1056/NEJMoa021423 Sohn, 2021, Obesity and the risk of primary liver cancer: a systematic review and meta-analysis, Clin Mol Hepatol, 27, 157, 10.3350/cmh.2020.0176 Jinjuvadia, 2014, The association between metabolic syndrome and hepatocellular carcinoma: systemic review and meta-analysis, J Clin Gastroenterol, 48, 172, 10.1097/MCG.0b013e3182a030c4 Sohn, 2016, Obesity and hepatocellular carcinoma, J Liver Cancer, 16, 86 Kim, 2022, Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver, Aliment Pharmacol Ther, 55, 97, 10.1111/apt.16706 Chan, 2017, Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B, J Gastroenterol Hepatol, 32, 667, 10.1111/jgh.13536 Kim, 2014, 2014 Clinical practice guidelines for overweight and obesity in Korea, Endocrinol Metab (Seoul), 29, 405, 10.3803/EnM.2014.29.4.405 Williams, 2018, 2018 ESC/ESH guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH), Eur Heart J, 39, 3021, 10.1093/eurheartj/ehy339 Larson, 2020, 2018 Korean Society of Hypertension guideline for the management of hypertension: a comparison of American, European, and Korean blood pressure guidelines, Eur Heart J, 41, 1384, 10.1093/eurheartj/ehaa114 2014, Diagnosis and classification of diabetes mellitus, Diabetes care, 37, S81, 10.2337/dc14-S081 Saverymuttu, 1986, Ultrasound scanning in the detection of hepatic fibrosis and steatosis, Br Med J (Clin Res Ed), 292, 13, 10.1136/bmj.292.6512.13 Younossi, 2016, Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, 64, 73, 10.1002/hep.28431 2016, Obes Facts, 9, 65, 10.1159/000443344 2015, 2014 KLCSG-NCC Korea Practice Guideline for the management of hepatocellular carcinoma, Gut Liver, 9, 267 Lee, 2019, Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B, Clin Mol Hepatol, 25, 52, 10.3350/cmh.2018.0040 Kim, 2019, Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir, Clin Mol Hepatol, 25, 283, 10.3350/cmh.2018.0054 Li, 2021, Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B, J Infect Dis, 224, 294, 10.1093/infdis/jiaa739 Oh, 2021, Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy, Hepatol Int, 15, 892, 10.1007/s12072-021-10205-7 Yoo, 2019, Clinical application of liver stiffness measurement for assessing the risk of hepatocellular carcinoma, J Liver Cancer, 19, 12 van der Poorten, 2013, Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause?, Hepatology, 57, 2180, 10.1002/hep.26072 Budd, 2020, Role of agents for the treatment of diabetes in the management of nonalcoholic fatty liver disease, Curr Diab Rep, 20, 59, 10.1007/s11892-020-01349-1 Michelotti, 2021, NAFLD-related hepatocarcinoma: the malignant side of metabolic syndrome, Cells, 10, 2034, 10.3390/cells10082034 Wai-Sun Wong, 2021, On the proposed definition of metabolic-associated fatty liver disease, Clin Gastroenterol Hepatol, 19, 865, 10.1016/j.cgh.2021.01.017 Wong, 2021, Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease, Clin Gastroenterol Hepatol, 19, 2161, 10.1016/j.cgh.2020.10.046 Eslam, 2022, Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight, Nat Rev Gastroenterol Hepatol, 19, 638, 10.1038/s41575-022-00635-5 Leung, 2017, Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients, Hepatology, 65, 54, 10.1002/hep.28697 Won, 2018, Hepatocellular carcinoma prediction models for patients with chronic Hhepatitis B virus infection in the era of potent antiviral therapy, J Liver Cancer, 18, 87